Gracell Biotechnologies Statistics Share Statistics Gracell Biotechnologies has 96.57M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 96.57M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 33.01M Failed to Deliver (FTD) Shares 145,000 FTD / Avg. Volume 9.9%
Short Selling Information The latest short interest is 521.21K, so 0% of the outstanding
shares have been sold short.
Short Interest 521.21K Short % of Shares Out n/a Short % of Float 0.68% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.35 and the forward
PE ratio is null.
Gracell Biotechnologies's PEG ratio is
-0.01.
PE Ratio -0.35 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.16 P/FCF Ratio -0.06 PEG Ratio -0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Gracell Biotechnologies.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.78,
with a Debt / Equity ratio of 0.13.
Current Ratio 6.78 Quick Ratio 6.9 Debt / Equity 0.13 Debt / EBITDA -0.31 Debt / FCF -0.05 Interest Coverage -92.72
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.93M Employee Count 314 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 22K Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is -0.34, so Gracell Biotechnologies's
price volatility has been lower than the market average.
Beta -0.34 52-Week Price Change n/a 50-Day Moving Average 9.23 200-Day Moving Average 5.05 Relative Strength Index (RSI) 68.18 Average Volume (20 Days) 1,464,475
Income Statement
Revenue n/a Gross Profit n/a Operating Income -624.66M Net Income -607.51M EBITDA -592.58M EBIT -600.75M Earnings Per Share (EPS) -44.85
Full Income Statement Balance Sheet The company has 1.45B in cash and 182.98M in
debt, giving a net cash position of 1.27B.
Cash & Cash Equivalents 1.45B Total Debt 182.98M Net Cash 1.27B Retained Earnings -1.63B Total Assets 1.89B Working Capital 1.54B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -3.31B
and capital expenditures -331.55M, giving a free cash flow of -3.64B.
Operating Cash Flow -3.31B Capital Expenditures -331.55M Free Cash Flow -3.64B FCF Per Share -268.73
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
